- Home
- GGT vs UNCY Comparison
GGT vs UNCY Comparison
Compare GGT & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGT | UNCY |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8M | 126.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GGT | UNCY |
|---|---|---|
| Price | $4.21 | $6.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 59.7K | ★ 351.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.32 | $3.71 |
| 52 Week High | $7.00 | $11.00 |
Technical Indicators
Market Signals| Indicator | GGT | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 54.75 |
| Support Level | $4.11 | $5.36 |
| Resistance Level | $4.25 | $5.95 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 78.89 | 72.63 |
Price Performance
Historical ComparisonAbout GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.